Switching Between GLP-1 Medications: The Complete Protocol Guide

Switching between GLP-1 medications is increasingly common: patients plateau on semaglutide and want to try tirzepatide, commercial insurance starts covering Zepbound so patients move off Wegovy, a compounded vial supply problem pushes patients back to brand-name pens, or the new Foundayo (oral orforglipron) becomes an option for patients who hate injections. Each switching scenario has a different protocol, a different washout period, and different dose-mapping considerations. This guide walks through every common switch with the FDA-label-supported washout timing and the practical dose equivalence tables. Any actual switching decision belongs between you and your prescriber — this is an educational explainer, not a dose recommendation.

Can you switch between GLP-1s?

Yes, switching is clinically routine and happens for several legitimate reasons [5]:

• Plateau or non-response. A patient on semaglutide 2.4 mg at maintenance who has truly stopped losing weight after week 40 may benefit from switching to tirzepatide, which produced larger mean weight loss in SURMOUNT-1 than STEP-1 reported for semaglutide [1, 2].
• Insurance coverage changes. The most common real-world reason. An employer adds Zepbound to the formulary, or Wegovy goes off, or a patient moves to a plan with different anti-obesity drug coverage, and they need to switch drugs mid-therapy.
• Side effect intolerance. Some patients tolerate tirzepatide's GI side-effect profile better than semaglutide, or vice versa. Switching is the clean way to test the other option.
• Supply shortages. Compounded supply can become unreliable when 503A pharmacies cycle on and off the FDA shortage list, pushing patients onto brand-name pens. Brand-name supply has also had intermittent shortages.
• Price changes. The Foundayo launch at $149/month self-pay has created a new price floor that will drive some patients off compounded vials.

General switching principles

Across every scenario, a few common rules apply [3, 4, 5]:

1. Don't combine GLP-1s. Both the Wegovy and Zepbound prescribing information explicitly say: do not use the drug in combination with any other GLP-1 receptor agonist [3, 4]. When switching, the old drug stops and the new drug starts — no overlap.
2. Time the switch to your next scheduled injection. Both semaglutide and tirzepatide are weekly drugs with ~5-7 day half-lives [3, 4]. The cleanest switch happens at the natural weekly injection point — skip the next dose of the old drug and take the first dose of the new drug in its place.
3. Restart the titration ramp on the new drug. The FDA-approved titration schedules exist to let the GI tract adapt to the GLP-1 mechanism. Even if you were already at maintenance on the old drug, the new drug should start at its lowest approved dose (0.25 mg for semaglutide; 2.5 mg for tirzepatide) and ramp up on the standard 4-week schedule [3, 4]. Skipping the ramp produces predictable severe nausea.
4. Do not expect the titration period to be “wasted time.” Patients switching from maintenance-dose sema to tirz assume they'll just continue losing weight on the new drug's starter dose. In practice, during the 16-20 weeks it takes to re-titrate, weight loss slows significantly — you may even see a small regain during the early ramp weeks. This is expected and the curve usually catches up once maintenance is reached on the new drug.

Scenario 1: Semaglutide → Tirzepatide (the most common switch)

This is the most-searched switching scenario (~600 combined monthly Google queries for “can you switch from semaglutide to tirzepatide” and variants). Typical patient profile: on Wegovy 2.4 mg or Ozempic for weight loss, plateaued or wants larger effect, insurance now covers Zepbound.

Protocol

1. Finalize with your prescriber. They write a new tirzepatide prescription and cancel the remaining semaglutide refills (or advise you to discard remaining doses).
2. Take your last semaglutide dose on your regular injection day. This is day 0.
3. One week later (day 7 — your next scheduled injection day), start tirzepatide 2.5 mg. This is the FDA-approved starter dose for Zepbound [4]. Do not start at a higher dose even if you were on maintenance semaglutide — the tirzepatide titration schedule exists for GI tolerance and skipping it produces severe nausea.
4. Follow the standard tirzepatide titration ramp: 2.5 mg for 4 weeks → 5 mg for 4 weeks → 7.5 mg for 4 weeks → 10 mg for 4 weeks → 12.5 mg for 4 weeks → 15 mg maintenance [4]. Most prescribers settle patients at 10 mg or 15 mg depending on response and tolerability.

What to expect

• Weeks 1-4 on 2.5 mg: Mild GI symptoms (nausea especially in days 1-3). Appetite suppression may feel weaker than you remember on maintenance semaglutide because you're back at the lowest dose.
• Weeks 4-8 on 5 mg: Appetite suppression strengthens. You should feel similar to where you were on 1 mg semaglutide.
• Weeks 12-16 (on 7.5 to 10 mg): You generally match or exceed your previous semaglutide effect.
• Weeks 20-24 (10-15 mg maintenance): You reach the full tirzepatide effect. Expected continued loss from this point forward if you still have additional fat mass to lose.

Scenario 2: Tirzepatide → Semaglutide

Less common than sema → tirz, but happens for insurance reasons or when tirzepatide side effects are intolerable and the patient wants to try the (slightly milder but similar) semaglutide.

Protocol

1. Take your last tirzepatide dose on your regular day.
2. One week later, start semaglutide 0.25 mg. FDA-approved starter dose for Wegovy and Ozempic [3].
3. Standard semaglutide titration ramp: 0.25 mg for 4 weeks → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg maintenance (Wegovy) or 2 mg maintenance (Ozempic).

Expect weight loss to be modestly smaller than it was on tirzepatide at equivalent timepoints based on the trial-arm comparisons [1, 2], but with potentially better GI tolerability at maintenance.

Scenario 3: Ozempic → Wegovy (same drug, different label)

Ozempic and Wegovy are both semaglutide manufactured by Novo Nordisk — same molecule, same manufacturer, different FDA labels and different maximum doses [3]. Ozempic's diabetes label caps at 2 mg weekly; Wegovy's weight- management label goes up to 2.4 mg weekly. The switch is primarily about insurance (Ozempic often covered for T2D patients, Wegovy for obesity).

Protocol

1. Wegovy dose strengths. Per the Wegovy FDA label Section 3 [3], the available pen strengths are 0.25, 0.5, 1.0, 1.7, and 2.4 mg only — there is no “Wegovy 2 mg” pen. If you are already at Ozempic 2 mg, your prescriber will typically transition you to either Wegovy 1.7 mg (the next step down on the Wegovy ladder) or directly to 2.4 mg, depending on tolerability and clinical goals.
2. If on a lower Ozempic dose (0.5 mg, 1 mg), continue at the matching Wegovy strength (0.5 mg or 1 mg) — the molecule is identical, so there's no need to re-titrate from the starter dose.

This is the cleanest switch in the category: no washout, no re-titration, just a pharmacy/insurance change.

Scenario 4: Wegovy → Zepbound (or vice versa)

This is a different-molecule switch (semaglutide to tirzepatide), so treat it like Scenario 1 — last semaglutide dose, skip one week, start tirzepatide at 2.5 mg and ramp up. The commercial-insurance reality in 2026 is that many plans now cover Zepbound specifically for weight management, which is pushing many Wegovy patients to switch.

Scenario 5: Brand-name → Compounded

Patients who can't afford brand-name pens often move to compounded vials through a telehealth provider. The same-molecule rule applies:

• Wegovy/Ozempic → compounded semaglutide: Same molecule. Continue at the same mg dose level. The main operational change is the injection format (pen → vial with insulin syringe), which requires learning the unit-vs-mg conversion (see our unit converter).
• Zepbound/Mounjaro → compounded tirzepatide: Same molecule. Same dose continuation. Same operational change to the vial-and-syringe format.

The clinical switch is trivial because the active drug is the same. The technical switch (learning to draw a dose from a vial with an insulin syringe) is the main new thing to adapt to. See our pen vs compounded vial deep-dive for the full operational comparison.

Scenario 6: Compounded → Brand-name

Patients switching back to brand-name pens (usually because they got insurance coverage, or because of quality concerns about a specific compounding pharmacy). Same rules as the reverse: same molecule, same dose, new delivery format.

Scenario 7: Injectable → Foundayo (oral orforglipron)

Foundayo was FDA-approved in April 2026 and is a different molecule than semaglutide or tirzepatide — it's a non-peptide small-molecule GLP-1 agonist. Patients switching from injectable sema or tirz to oral Foundayo are making both a drug change and a delivery-format change.

Protocol

1. Take your last injectable dose on the regular day.
2. Skip one week, then start Foundayo 0.8 mg orally once daily (the FDA-approved starter dose).
3. Follow the Foundayo titration ramp: 0.8 mg → 2.5 mg → 5.5 mg → 9 mg → 14.5 mg → 17.2 mg, with at least 30 days between dose increases per the Foundayo FDA label.

Expect the full effect to be smaller than injectable tirzepatide (~12% vs ~21% at comparable timepoints based on ATTAIN-1 vs SURMOUNT-1) but with the convenience of a daily pill with no food restrictions. See our Foundayo approval deep-dive for the full trial data.

For the specific Foundayo ↔ Zepbound switching question — including the side-by-side §2 dose ranges of both labels, the cross-trial efficacy comparison (ATTAIN-1 −11.1% at 17.2 mg vs SURMOUNT-1 −20.9% at 15 mg, 72 weeks each), the practical re-titration pattern when switching, and the oral-contraceptive label-asymmetry that affects patients of reproductive potential — see our companion Foundayo ↔ Zepbound switch dose-equivalence guide. There is no FDA-approved equivalence table; switching between these two specific drugs is a prescriber decision anchored to the receiving drug's §2 missed-dose rule.

Why there is no semaglutide-to-tirzepatide dose equivalence table

There is no formal FDA-approved dose equivalence between semaglutide and tirzepatide. The two molecules target different receptors (semaglutide is a pure GLP-1 agonist; tirzepatide is a dual GIP/GLP-1 agonist), the dose-response curves are not parallel, and the only direct head-to-head randomized comparison — SURPASS-2 (Frias et al., NEJM 2021, PMID 34170647) in patients with type 2 diabetes — found that even the lowest tirzepatide dose (5 mg) produced greater HbA1c and weight reduction than semaglutide 1 mg. That finding rules out any clean “1 mg sema = 5 mg tirz” mapping.

Practically, this means a prescriber switching a patient from semaglutide to tirzepatide will restart at the FDA-approved tirzepatide starter dose (2.5 mg) and titrate on the standard 4-week schedule, regardless of what semaglutide dose the patient was on. The reverse switch (tirz → sema) restarts at semaglutide 0.25 mg with the standard ramp. Trying to “match” the prior dose level on the new molecule is not supported by any head-to-head randomized data and is not how the labels are written [3, 4].

Common switching mistakes to avoid

1. Combining two GLP-1s. Both drugs' FDA labels prohibit this [3, 4]. Do not take your last semaglutide dose and the first tirzepatide dose on the same day. Skip the next scheduled dose of the old drug.
2. Skipping the new drug's titration ramp. “I was at maintenance on the old drug so I'll start the new one at maintenance too” — this produces severe nausea and frequently leads to discontinuation. The titration schedule exists because the GI tract needs to re-adapt to the new molecule, not because the nervous system needs to re-adapt to GLP-1 signaling in general.
3. Not understanding the weight-loss pause during re-titration. The 16-20 week ramp on the new drug usually produces slower weight loss or even minor regain before the curve catches up. This is not a failure — it's the shape of the curve. See our onset guide for week-by-week expectations.
4. Switching drugs when the real problem is technique. Many patients who think they've plateaued have actually developed lipohypertrophy at a favorite injection site, or are miscalculating the unit-to-mg conversion on a compounded vial. Fix those first. See our plateau guide.

Related research and tools

For the brand-name cheat sheet that disambiguates which product equals which molecule, see our brand cheat sheet. For the plateau diagnosis flow that determines whether you should actually switch, see our plateau guide. For the unit-vs-mg conversion when switching from pens to compounded vials (or back), use our unit converter. For the expected week-by-week curve on each drug, use our weight loss calculator. For the injection technique that stays the same across all switches, see our injection guide. For the specific Wegovy ↔ Zepbound switch question — including the verbatim §2 dose ranges of both DailyMed labels, the SURMOUNT-5 head-to-head efficacy + safety data (PMID 40353578 — the only direct head-to-head trial), the cross-trial caveats from STEP-1 vs SURMOUNT-1, the re-titration logic in either direction, and the CVS Caremark July 2025 formulary swap that drove most current switch volume — see our Wegovy ↔ Zepbound switch dose-equivalence guide.